SecBot SecBot

MRNA drug pipeline

Moderna, Inc. · 4 rated drugs
$215.27
−3.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.5%
1-day, median of 3 events
IV rank
29
IV 82% · HV 106%
Rated drugs
4
1 bullish · 3 neutral
Phase 3 trials
3
2 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled / PDUFA (Phase 3 completed)
Time to marketPDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.

mRNA-1010 Updated Jun 30

What to watch

Watch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.

Bull case
  • Pivotal Phase 3 data published in the New England Journal of Medicine (May 7, 2026) showed mRNA-1010 was superior to standard-dose licensed flu vaccines in adults 50+, a clear efficacy win for the mRNA platform beyond COVID (source: NEJM).
  • FDA advisory committee (VRBPAC) voted 9-0 unanimously on June 18, 2026 that the vaccine's benefits outweigh risks, a near-necessary precondition for approval, with the FDA historically following such votes in the vast majority of cases (source: FDA catalyst data + Ars Technica).
  • If approved by the August 5 PDUFA date, mRNA-1010 would be the first-ever mRNA-based influenza vaccine on the US market, giving Moderna first-mover advantage in a large, recurring annual market dominated by older egg/cell-based technologies (source: Clinical Trials Arena).
Bear case
  • The stock has already rallied over 140% from its 52-week low of $22.28 to ~$71, meaning much of the flu vaccine approval story is already priced in. Mean analyst price target is $44.25, the stock trades well above consensus.
  • Analyst consensus is a Hold (19 Hold, 4 Buy, 4 Sell, 3 Strong Sell) with zero upgrades or downgrades in the last 90 days, suggesting Wall Street is not chasing this rally (source: analyst data).
  • The FDA's initial Refusal-to-File letter (February 2026) shows the agency had concerns about the submission, though reversed, this signals regulatory risk is non-zero even after a positive AdCom (source: HTR Media / National Law Review).
● neutral
Impact
PhasePhase 3 (completed)
Time to marketBLA submission planned by end of 2026; regulatory approval targeted for 2027 if the FDA accepts and reviews the application on a standard timeline.

intismeran intismeran autogene Updated Nov 9

What to watch

Watch for Moderna's BLA submission for intismeran in melanoma by end of 2026. A submission would confirm the regulatory path is on track, while any delay would be a negative signal. The actual PDUFA decision (likely in 2027) is the true binary catalyst. The stock has already rallied ~978% over the past year, and the mean analyst price target of $145 implies ~42% downside from the current ~$259, suggesting much of the good news may already be priced in.

Bull case
  • Phase 3 INTerpath-001 trial met its primary endpoint: intismeran + Keytruda reduced risk of melanoma recurrence or death by 42% (HR=0.58, p<0.001) vs Keytruda alone in 1,137 patients with resected stage IIB-IV melanoma (per ESMO 2026 presentation and Reuters).
  • The drug also met the key secondary endpoint of distant metastasis-free survival, reducing risk of spread by 38%.
  • Intismeran is a potential first-in-class individualized neoantigen therapy (INT), a personalized mRNA cancer vaccine encoding up to 34 patient-specific neoantigens.
Bear case
  • Analyst consensus is 'hold' with a mean price target of $145.42, implying ~42.8% downside from the current ~$259 stock price.
  • The stock has already rallied ~978% over 12 months (per quant signals), suggesting much of the intismeran upside may already be priced in.
  • A Phase 3 trial of intismeran in cutaneous squamous cell carcinoma (NCT06295809) was terminated, limiting the initial addressable market to melanoma alone.
● neutral
Impact
PhasePhase 1/2
Time to marketSeveral years away, if ever. The drug is in Phase 1/2 dose-escalation; a registrational path has not been defined.

mRNA-2808 Updated Nov 9

What to watch

Watch for the full ASH 2026 oral presentation in December 2026 for deeper efficacy and safety details (duration of response, cytokine release syndrome rates). The early 36% response rate in heavily pretreated patients is encouraging but very early. Moderna has a second T-cell engager (mRNA-2151) in ovarian cancer that could validate the platform if mRNA-2808 data holds up.

Bull case
  • Early data showed 4 confirmed responses among 11 heavily pretreated multiple myeloma patients (36% response rate), a meaningful signal in a difficult-to-treat population.
  • The multiplexed mRNA approach (encoding three anti-cancer proteins from a single drug) is novel and could offer advantages over traditional biologics manufacturing.
  • Moderna's Science Day in June 2026 highlighted mRNA-2808 as validation of the T-cell engager modality, supporting a second TCE (mRNA-2151) in ovarian cancer.
Bear case
  • The drug is in very early Phase 1/2 dose-escalation with only 11 patients reported; response rates often change as larger cohorts are enrolled.
  • Multiple myeloma is a crowded field with approved bispecific antibodies (e.g., teclistamab, elranatamab), CAR-T therapies (e.g., Carvykti, Abecma), and many other T-cell engagers in development from J&J, AbbVie, GSK, and others.
  • mRNA-2808 is a small part of Moderna's pipeline; the stock's 545%+ YTD rally in 2026 was driven primarily by the intismeran (personalized cancer vaccine) data and COVID vaccine sales, not this asset.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

mRNA-4203 Updated Nov 9

What to watch

mRNA-4203 does not appear in any public Moderna pipeline disclosures, clinical trial registries, or FDA catalyst lists as of November 2026. Investors should monitor Moderna's official pipeline page and quarterly earnings materials for any mention of this candidate. Until the company discloses the indication and development stage, the program is not a meaningful standalone catalyst for MRNA stock.

Bull case
  • Moderna's mRNA platform has demonstrated broad applicability across infectious disease vaccines (COVID-19, RSV, flu) and oncology, suggesting any new candidate leverages proven technology.
  • If mRNA-4203 targets a large market (e.g., a combination respiratory vaccine or a novel infectious disease target), it could eventually add to Moderna's pipeline optionality.
  • Moderna's stock has surged ~545% year-to-date in 2026, reflecting strong commercial execution and pipeline momentum that could support early-stage programs.
Bear case
  • No public information exists about mRNA-4203: no clinical trial, no disclosed indication, no mechanism of action, and no development timeline. It may be a discontinued, renamed, or never-active program.
  • Moderna's pipeline is already crowded with high-profile programs (intismeran oncology, mRNA-1345 RSV, mRNA-1647 CMV, mRNA-1010 flu), and an undisclosed early-stage candidate faces long odds of ever reaching the market.
  • The mean analyst price target for MRNA is $145.42, implying roughly 43% downside from the current ~$258 price, suggesting the stock already prices in substantial pipeline optimism.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Aug 5, 2026mRNA-1010PDUFA decision−5.5%+11.7%
Jul 31, 2026mRESVIAApproval−4.8%+2.2%
Feb 13, 2026mRNA-1010Refuse to file+9.5%+25.4%

Clinical trials

12 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
mRNA-1647A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Phase 2Active not recruiting84Aug 1, 2026
mRNA-1468A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgePhase 2Active not recruiting659Jun 30, 2026
mRNA-1345A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersPhase 2Completed360May 25, 2026
mRNA-1647A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgePhase 2Completed873May 12, 2026
mRNA-3705A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaPhase 2Terminated18Apr 1, 2026
mRNA-1345A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgePhase 3Completed507Mar 27, 2026
mRNA-1647A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccinePhase 2Completed135Jan 19, 2026
mRNA-1608A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesPhase 2Completed · results303Apr 25, 2025
mRNA-1283.222A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19Phase 3Completed · results13,553Apr 12, 2025
Moderna mRNA-1273Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of ConcernPhase 3Completed · results14,237Apr 19, 2024
Moderna mRNA-1273COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersPhase 2Terminated · results258Jun 22, 2023
mRNA-1647Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsPhase 2Completed · results315Jan 4, 2023